Modality
Degrader
MOA
PI3Ki
Target
PI3Kα
Pathway
PI3K/AKT
Bladder Ca
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
Dec 2020
→ Aug 2028
Phase 1Current
NCT04842165
1,207 pts·Bladder Ca
2020-12→2028-08·Not yet recruiting
1,207 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-122.4y awayPh2 Data· Bladder Ca
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2028-08-12 · 2.4y away
Bladder Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04842165 | Phase 1/2 | Bladder Ca | Not yet recr... | 1207 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα |